Design, synthesis, biological evaluation and molecular docking study of 2,4-diarylimidazoles and 2,4-bis(benzyloxy)-5-arylpyrimidines as novel HSP90 N-terminal inhibitors

References

• Freilich R, Arhar T, Abrams JL, Gestwicki JE. Protein-protein interactions in the molecular chaperone network. Acc Chem Res. 2018;51(4):940–949.
   PubMed Web of Science ®Google Scholar
• Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU. Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem. 2013;82:323–355.
   PubMed Web of Science ®Google Scholar
• Hoter A, El-Sabban ME, Naim HY. The HSP90 family: structure, regulation, function, and implications in health and disease. IJMS. 2018;19(9):2560.
   Google Scholar
• Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18(6):345–360.
   PubMed Web of Science ®Google Scholar
• Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci. 2002;59(10):1640–1648.
   PubMed Web of Science ®Google Scholar
• Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761–772.
   PubMed Web of Science ®Google Scholar
• Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425(6956):407–410.
   PubMed Web of Science ®Google Scholar
• Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des. 2013;19(3):347–365.
   PubMed Web of Science ®Google Scholar
• Serwetnyk MA, Blagg BSJ. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition. Acta Pharm Sin B. 2021;11(6):1446–1468.
   PubMed Web of Science ®Google Scholar
• Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537–549.
   PubMed Web of Science ®Google Scholar
• Bohush A, Bieganowski P, Filipek A. Hsp90 and its co-chaperones in neurodegenerative diseases. IJMS. 2019;20(20):4976.
   Google Scholar
• Fuhrmann-Stroissnigg H, Ling YY, Zhao J, McGowan SJ, Zhu Y, Brooks RW, Grassi D, Gregg SQ, Stripay JL, Dorronsoro A, et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat Commun. 2017;8(1):422.
   PubMed Web of Science ®Google Scholar
• Huang DS, LeBlanc EV, Shekhar-Guturja T, Robbins N, Krysan DJ, Pizarro J, Whitesell L, Cowen LE, Brown LE. Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors. J Med Chem. 2020;63(5):2139–2180.
   PubMed Web of Science ®Google Scholar
• Lubkowska A, Pluta W, Strońska A, Lalko A. Role of heat shock proteins (HSP70 and HSP90) in viral infection. IJMS. 2021;22(17):9366.
   Google Scholar
• Noddings CM, Wang RY-R, Johnson JL, Agard DA. Structure of Hsp90-p23-GR reveals the Hsp90 client-remodelling mechanism. Nature. 2022;601(7893):465–469.
   PubMed Web of Science ®Google Scholar
• Verba KA, Wang RY-R, Arakawa A, Liu Y, Shirouzu M, Yokoyama S, Agard DA. Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase. Science. 2016;352(6293):1542–1547.
   PubMed Web of Science ®Google Scholar
• Li L, Chen N-N, You Q-D, Xu X-L. An updated patent review of anticancer Hsp90 inhibitors (2013-present). Expert Opin Ther Pat. 2021;31(1):67–80.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Liu Y. Recent advances in the discovery of novel HSP90 inhibitors: an update from 2014. Curr Drug Targets. 2020;21(3):302–317.
   PubMed Web of Science ®Google Scholar
• Bickel D, Gohlke H. C-terminal modulators of heat shock protein of 90 kDa (HSP90): state of development and modes of action. Bioorg Med Chem. 2019;27(21):115080.
   PubMed Web of Science ®Google Scholar
• Wang Y, Mcalpine SR. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. Chem Commun. 2015;51(8):1410–1413.
   PubMed Web of Science ®Google Scholar
• Li L, Wang L, You Q-D, Xu X-L. Heat shock protein 90 inhibitors: an update on achievements, challenges, and future directions. J Med Chem. 2020;63(5):1798–1822.
   PubMed Web of Science ®Google Scholar
• Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, et al. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. Mol Syst Biol. 2018;14(3):e7858.
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, et al. Combined BRAF and HSP90 inhibition in patients with unresectable BRAF (V600E)-mutant melanoma. Clin Cancer Res. 2018;24(22):5516–5524.
   PubMed Web of Science ®Google Scholar
• Birbo B, Madu EE, Madu CO, Jain A, Lu Y. Role of HSP90 in cancer. IJMS. 2021;22(19):10317.
   Google Scholar
• Solárová Z, Mojžiš J, Solár P. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). Int J Oncol. 2015; 46(3):907–926.
   PubMed Web of Science ®Google Scholar
• Mortensen ACL, Mohajershojai T, Hariri M, Pettersson M, Spiegelberg D. Overcoming limitations of cisplatin therapy by additional treatment with the HSP90 inhibitor onalespib. Front Oncol. 2020;10(532285):532285.
   PubMedGoogle Scholar
• Liu Y, Liu X, Li L, Dai R, Shi M, Xue H, Liu Y, Wang H. Identification and structure-activity studies of 1,3-Dibenzyl-2-aryl imidazolidines as novel Hsp90 inhibitors. Molecules. 2019;24(11):2105.
   PubMed Web of Science ®Google Scholar
• Hwang JY, Kim H-Y, Jo S, Park E, Choi J, Kong S, Park D-S, Heo JM, Lee JS, Ko Y, et al. Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors. Eur J Med Chem. 2013;70:315–325.
   PubMed Web of Science ®Google Scholar
• Godin G, Levrand B, Trachsel A, Lehn J-M, Herrmann A. Reversible formation of aminals: a new strategy to control the release of bioactive volatiles from dynamic mixtures. Chem Commun. 2010;46(18):3125–3127.
   PubMed Web of Science ®Google Scholar
• Buchs Née Levrand B, Godin G, Trachsel A, de Saint Laumer J-Y, Lehn J-M, Herrmann A. Reversible aminal formation: controlling the evaporation of bioactive volatiles by dynamic combinatorial/covalent chemistry. Eur J Org Chem. 2011;2011(4):681–695.
   Web of Science ®Google Scholar
• Zhang L, Peng X-M, Damu GLV, Geng R-X, Zhou C-H. Comprehensive review in current developments of imidazole-based medicinal chemistry. Med Res Rev. 2014;34(2):340–437.
   PubMed Web of Science ®Google Scholar
• Jeelan BN, Goudgaon NM. A comprehensive review on pyrimidine analogs-versatile scaffold with medicinal and biological potential. J Mol Struct. 2021;1246:131168.
   Web of Science ®Google Scholar
• Senecal TD, Shu W, Buchwald SL. A general, practical palladium-catalyzed cyanation of (hetero)aryl chlorides and bromides. Angew Chem Int Ed Engl. 2013;52(38):10035–10039.
   PubMed Web of Science ®Google Scholar
• Wang D, Haseltine J. A comparison of phenylboronic acid and phenyltrimethyltin in the palladium-catalyzed arylation of 1,5-dialkylimidazoles. J Heter Chem. 1994;31(6):1637–1639.
   Web of Science ®Google Scholar
• O'Connell JF, Parquette J, Yelle WE, Wang W, Rapoport H. Convenient synthesis of methyl 1-methyl-2,4-dibromo-5-imidazolecarboxylate. Synthesis. 1988;1988(10):767–771.
   Google Scholar
• Li B, Chiu CK-F, Hank RF, Murry J, Roth J, Tobiassen H. An optimized process for formation of 2,4-disubstituted imidazoles from condensation of amidines and α-haloketones. Org Process Res Dev. 2002;6(5):682–683. − 
   Web of Science ®Google Scholar
• Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. 1997;89(2):239–250.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos M-A, Psaltopoulou T. Hsp90 inhibitors in breast cancer: a systematic review. Breast. 2013;22(5):569–578.
   PubMedGoogle Scholar
• Song M, Bode AM, Dong Z, Lee M-H. AKT as a therapeutic target for cancer. Cancer Res. 2019;79(6):1019–1031.
   PubMed Web of Science ®Google Scholar
• Liu F, Yang X, Geng M, Huang M. Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 2018;8(4):552–562.
   PubMed Web of Science ®Google Scholar
• Howes R, Barril X, Dymock BW, Grant K, Northfield CJ, Robertson AGS, Surgenor A, Wayne J, Wright L, James K, et al. A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem. 2006;350(2):202–213.
   PubMed Web of Science ®Google Scholar